Jeff P. Sharman, MD, discusses the safety profile of acalabrutinib that was demonstrated in the phase III ELEVATE-TN trial. The trial evaluated acalabrutinib as a single agent or in combination with obinutuzumab versus…
During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in…
In this video, John M. Burke, MD, from Rocky Mountain Cancer Centers explores the potential impacts of new weight loss medications, such as GLP-1 agonists,…
Amy Selly, CNP, AOCNP, discusses the different definitions of cancer survivorship.
Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new treatment options in oncology.
Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, but diagnostic criteria and terminology have been…
A real-world analysis of cilta-cel in patients with relapsed/refractory multiple myeloma showed deep and durable responses, with a safety profile consistent with clinical trial data.
The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.
Anil Parwani, MD, PhD, explains his visions and plans for further development and integration of artificial intelligence technology in cancer diagnosis and prognosis.
In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent…
Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented at the 2024 ESMO Congress.
